BioSpace News Archive

Sumitomo Chemical Co., Ltd., parent company of Valent U.S.A. and Valent Biosciences, announced a new entity called Valent North America that will provide enterprise business services across the Valent group of companies.

Kubota Vision Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced positive results from a post hoc analysis of the phase 3 clinical trial of the investigational visual cycle modulator emixustat hydrochloride in patients with Stargardt Disease.

Edinburgh and Cambridge, UK, 03 October 2022 - Macomics Ltd, a biotech company with world-leading expertise in macrophage biology, congratulates its co-founder Prof. Jeffery Pollard Ph.D. on his election to the Academia Europaea (the European Academy, AE).

The world is experiencing a crisis in pain management and prescription drug abuse. Over the last decade, strategies to help curb the prescription drug crisis have included the development of Abuse Deterrent Formulations (ADF’s) to release the drug slowly over time and other measures.

Boston Heart Diagnostics is pleased to announce the availability of LipoMap™.

SwRI’s multidisciplinary staff conducts R&D for government, industry clients worldwide Dr. Joe McDonough has been named vice president of Southwest Research Institute’s Chemistry and Chemical Engineering Division.

Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced the completion of its previously announced transaction to be acquired by Patient Square Capital, a leading dedicated health care investment firm, in an all-cash transaction.

Grifols announced changes to its leadership team, appointing Mr. Steven F. Mayer as Executive Chairperson while Mr. Victor Grifols Roura retired as Chairperson and was named Chairperson of Honor.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the 1st Symposium on IRAK4 in Cancer taking place virtually on October 7, 9:00am-1:00pm ET.

First of three approved U.S. oncology biosimilars Amneal expects to launch Amneal Pharmaceuticals, Inc. announced the commercial launch of ALYMSYS®, a biosimilar referencing Avastin®.